Robotic Biopsy Devices Market Size, Share and Trends 2026 to 2035

According to MarketnReports, the global Robotic Biopsy Devices market size was estimated at USD 80 million in 2025 and is expected to reach USD 180 million by 2035, growing at a CAGR of 8.7% from 2026 to 2035. Rising cancer prevalence and the demand for precise, minimally invasive tissue sampling procedures.

What are the Key Insights of the Robotic Biopsy Devices Market?

  • The global Robotic Biopsy Devices market is expected to be valued at USD 80 million in 2025 and reach USD 180 million by 2035.
  • The market is projected to grow at a CAGR of 8.7% from 2026 to 2035.
  • The market is driven by increasing cancer incidence and advancements in robotic precision for minimally invasive diagnostics.
  • The robotic biopsy systems segment dominates the product segment with approximately 55% share because of its integration of real-time imaging, AI navigation, and superior accuracy in complex procedures.
  • The lung biopsy segment dominates the application segment with 35% share due to high lung cancer prevalence and the need for precise sampling of peripheral nodules.
  • The hospitals segment dominates the end-use segment with 51% share owing to advanced infrastructure and ability to adopt capital-intensive robotic technologies.
  • North America dominates the global market with around 58% share due to strong healthcare infrastructure, reimbursement policies, and early adoption of advanced robotic systems.

What is the Robotic Biopsy Devices Market?

Industry Overview

The robotic biopsy devices market involves advanced medical systems that integrate robotics, real-time imaging, and AI-assisted navigation to perform precise, minimally invasive tissue biopsies for diagnosing cancers and chronic diseases. These devices enhance accuracy, reduce complications, and improve patient outcomes compared to traditional manual methods by enabling better targeting of hard-to-reach lesions in organs like the lungs, prostate, and brain. The market supports early detection initiatives through high-precision sampling, contributing to oncology diagnostics and personalized medicine.

What are the Market Dynamics of the Robotic Biopsy Devices Market?

Growth Drivers

Growth drivers include the rising global cancer burden, particularly lung and prostate cancers, prompting demand for early and accurate diagnosis. Technological advancements in robotics, AI integration, and imaging enhance procedural precision and safety, encouraging adoption. Increasing preference for minimally invasive techniques reduces patient recovery time and complications, while government initiatives for cancer screening further propel market expansion.

Restraints

Restraints encompass high acquisition and maintenance costs of robotic systems, limiting adoption in resource-constrained settings and smaller facilities. The need for specialized training for surgeons and radiologists, along with regulatory hurdles for new devices, slows widespread implementation. Variability in reimbursement policies across regions also poses barriers to market penetration.

Opportunities

Opportunities lie in expanding applications to emerging markets with growing healthcare investments and rising cancer rates. Innovations in compact, portable systems suitable for outpatient and ambulatory settings can broaden accessibility. Integration of AI and IoT for improved outcomes, along with partnerships for clinical validation, opens avenues for new product development and market growth.

Challenges

Challenges involve addressing training gaps and ensuring consistent procedural outcomes across diverse healthcare settings. Regulatory complexities and lengthy approval processes for advanced robotic platforms hinder rapid innovation. Competition from traditional biopsy methods and supply chain issues for specialized components remain ongoing hurdles.

Robotic Biopsy Devices Market: Report Scope

Report Attributes Report Details
Report Name Robotic Biopsy Devices Market
Market Size 2025 USD 80 million
Market Forecast 2035 USD 180 million
Growth Rate CAGR of 8.7%
Report Pages 220
Key Companies Covered

Medtronic, Renishaw plc, iSYS Medizintechnik GmbH, Biobot Surgical Pte Ltd, Intuitive Surgical Operations, Inc., and Others
Segments Covered By Product (Robotic Biopsy Systems, Instruments & Accessories), By Application (Lung Biopsy, Prostate Biopsy, Brain Biopsy, Others), By End-Use (Hospitals, Ambulatory Surgical Centers, Academic & Research Institutes), and By Region
Regions Covered North America, Europe, Asia Pacific (APAC), Latin America, and The Middle East and Africa (MEA)
Base Year 2025
Historical Year 2020 - 2024
Forecast Year 2026 - 2035
Customization Scope Avail customized purchase options to meet your exact research needs.

How is the Robotic Biopsy Devices Market Segmented?

The Robotic Biopsy Devices market is segmented by product, application, end-use, and region.

Based on Product Segment, the robotic biopsy systems segment is the most dominant, with 55% share, driven by its comprehensive integration of robotic arms, imaging, and AI for high-precision navigation in complex biopsies, significantly improving diagnostic yield and safety. The instruments & accessories segment is the second most dominant, supporting market growth by providing essential consumables and add-ons that ensure ongoing use and compatibility with core systems.

Based onthe  Application Segment, the lung biopsy segment is the most dominant with 35% share, fueled by the high incidence of lung cancer and the complexity of accessing peripheral lung lesions, where robotic guidance offers superior accuracy and reduced complications. The prostate biopsy segment is the second most dominant, benefiting from the need for precise targeting in prostate cancer diagnostics, driving market expansion through improved early detection and patient outcomes.

Based on the End-Use Segment, the hospitals segment is the most dominant with 51% share, as these facilities possess the necessary infrastructure, skilled personnel, and capital to invest in advanced robotic systems for high-volume diagnostic procedures. The ambulatory surgical centers segment is the second most dominant, contributing to growth by enabling cost-effective, outpatient biopsies with faster recovery and expanding access in urban areas.

What are the Recent Developments in the Robotic Biopsy Devices Market?

  • In 2025, Noah Medical's Galaxy System surpassed 5,000 procedures in the USA, demonstrating its integration of tomosynthesis and augmented fluoroscopy for enhanced precision in lung cancer diagnostics.
  • In 2025, Johnson & Johnson MedTech received FDA 510(k) clearance for MONARCH QUEST, an AI-powered upgrade to its MONARCH platform, integrating with GE HealthCare imaging for improved lung biopsy accuracy.

Which Region Dominates the Robotic Biopsy Devices Market?

  • North America is expected to dominate the global market.

North America leads due to advanced healthcare infrastructure, supportive reimbursement policies, high cancer prevalence, and early adoption of robotic technologies. The United States dominates within the region through strong government initiatives for cancer awareness and extensive R&D investments.

Europe follows closely, driven by aging populations, oncology research centers, and regulatory support for innovative diagnostics in countries like Germany and the UK.

Asia Pacific is the fastest-growing region, propelled by rising healthcare expenditures, increasing cancer incidence, and adoption in countries like China, Japan, and South Korea.

Latin America and the Middle East & Africa exhibit emerging growth, supported by improving medical infrastructure and growing awareness of advanced diagnostic tools.

Who are the Key Players in the Robotic Biopsy Devices Market?

  • Medtronic focuses on innovative robotic platforms with AI integration, strategic acquisitions, and partnerships to expand its presence in oncology diagnostics.
  • Renishaw plc emphasizes precision engineering in robotic biopsy systems, investing in R&D for high-accuracy navigation and global market penetration.
  • iSYS Medizintechnik GmbH specializes in compact robotic guidance systems, prioritizing regulatory approvals and collaborations for minimally invasive applications.
  • Biobot Surgical Pte Ltd develops targeted robotic solutions for prostate and other biopsies, focusing on clinical validation and Asia-Pacific expansion.
  • Intuitive Surgical Operations, Inc. leverages its surgical robotics expertise to advance biopsy applications, emphasizing system integration and training programs.

What are the Market Trends in the Robotic Biopsy Devices Market?

  • Increasing integration of AI and machine learning for real-time guidance and improved accuracy.
  • Shift toward outpatient and ambulatory settings for cost-effective, minimally invasive biopsies.
  • Growing emphasis on early cancer detection through precise robotic sampling.
  • Expansion of applications beyond the lung and prostate to the brain and other hard-to-reach areas.
  • Rising strategic partnerships and collaborations for technology development and market access.

What Market Segments and their Subsegments are Covered in the Report?

By Product

  • Robotic Biopsy Systems
  • Instruments & Accessories

By Application

  • Lung Biopsy
  • Prostate Biopsy
  • Brain Biopsy
  • Others

By End-Use

  • Hospitals
  • Ambulatory Surgical Centers
  • Academic & Research Institutes

By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • UAE
    • South Africa
    • Rest of Middle East & Africa

Frequently Asked Questions

Robotic biopsy devices are advanced systems using robotics, imaging, and AI for precise, minimally invasive tissue sampling to diagnose diseases like cancer.

Key factors include rising cancer prevalence, technological advancements in robotics and AI, demand for minimally invasive procedures, and supportive healthcare policies.

The market is expected to reach USD 180 million by 2035.

The CAGR is 8.7%.

North America will contribute notably due to advanced infrastructure and high adoption rates.

Major players include Medtronic, Renishaw plc, iSYS Medizintechnik GmbH, Biobot Surgical Pte Ltd, and Intuitive Surgical Operations, Inc.

The report provides detailed insights into market size, segments, trends, key players, regional dynamics, and forecasts.

Stages include R&D and design, manufacturing of systems and accessories, regulatory approvals, distribution to healthcare facilities, clinical use, and post-market support.

Preferences are shifting toward AI-enhanced, minimally invasive devices with better accuracy, faster recovery, and outpatient suitability.

Regulatory approvals like FDA clearances drive growth by ensuring safety, while environmental factors include sustainable manufacturing and reduced procedure waste.